Background: Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer. Objective: The European Society of Gynecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide. Methods: The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert These guidelines statements were developed by ESGO, ESTRO and ESP and are published in the International
Responsibilities
These guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician applying or consulting these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. These guidelines make no representations or warranties of any kind whatsoever regarding their content, use, or application and disclaim any responsibility for their application or use in any way.
Methods
The guidelines were developed using a 5-step process as defined by the European Society of Gynecological Oncology (ESGO) Guideline Committee (Fig. 1) . The strengths of the process include creation of a multidisciplinary international development group, use of scientific evidence and/or international expert consensus to support the guidelines, and use of an international external review process (physicians and patients). This development process involved 3 meetings of the international development group, chaired by Prof David Cibula (Charles University, Prague, Czech Republic), Prof Richard Pötter (Medical University of Vienna, Vienna, Austria), and Prof Maria Rosaria Raspollini (University Hospital, Careggi, Florence, Italy).
Step 1: Nomination of multidisciplinary international development group
The European Society of Gynecological Oncology/ European Society for Radiotherapy and Oncology (ESTRO)/ European Society of Pathology (ESP) nominated practicing clinicians who are involved in the management of cervical cancer patients and have demonstrated leadership in clinical management of patients through research, administrative responsibilities, and/or committee membership to serve on the expert panel. The objective was to assemble a multidisciplinary panel. It was therefore essential to include professionals from relevant disciplines (surgery, medical oncology, pathology, radiology, gynecology, radiation oncology) to contribute to the validity and acceptability of the guidelines. The experts of the multidisciplinary international development group were required to complete a declaration of interest form and to promptly inform the ESGO council if any change in the disclosed information occurred during the course of the work.
Step 2: Identification of scientific evidence
To ensure that the statements were evidence based, the current literature was reviewed and critically appraised. A systematic literature review of relevant studies published between January 1997 and January 2017 was carried out using the MEDLINE database (Supplementary Material 1). The literature search was limited to publications in English. Priority was given to highquality systematic reviews, meta-analyses, and randomized controlled trials, but studies of lower levels of evidence were also evaluated. The search strategy excluded editorials, letters, and in vitro studies. The reference list of each identified article was reviewed for other potentially relevant articles. The bibliography was also supplemented by additional references provided by the international development group. Another bibliographic search was carried out to identify previous initiatives using a systematic literature search in MEDLINE database (no restriction in the search period) and a bibliographic search using selected evidence-based medicine Web sites (Supplementary Material 2) . After the selection and critical appraisal of the articles whose full list of references is available on the ESGO website, a summary of the scientific evidence was developed.
Step 3: Formulation of guidelines
The multidisciplinary expert group developed guidelines for staging, FST, management (stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy, locally advanced cervical cancer, primary distant metastatic disease, CCIP, and recurrent disease), and follow-up for patients with cervical cancer. If an approach was judged to be acceptable but was not unanimously recognized as a criterionstandard clinical approach, indication was given that it was still subject to discussion and/or evaluation. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The reliability and quality of the evidence given throughout this article have been graded following the Scottish intercollegiate guidelines network grading system (Table 1) . Grading of principles of radiotherapy and principles of pathological evaluation according to this grading system is challenging and is beyond the scope of these guidelines.
Step 4: External evaluation of the guidelines -
International review
The ESGO/ESTRO/ESP consulted a large panel of practicing clinicians who are involved in the management of cervical cancer patients. Cervical cancer patients were also included. The objective was to assemble a multidisciplinary panel. The 159 international reviewers were independent from the multidisciplinary expert group. International reviewers were asked to evaluate each guideline according to their relevance and feasibility in clinical practice (only physicians). Quantitative and qualitative evaluations of the guidelines were performed. Patients were asked to qualitatively evaluate each guideline (according to their experience, preferences, feelings, etc).
Step 5: Integration of international reviewers comments
Responses of the 159 external reviewers were pooled and discussed by the international development group to finalize the guidelines.
The complete report for the management of patients with cervical cancer contains the comprehensive literature review (indicating the level of evidence), justifications for selected recommendations, and the guidelines (indicating the grading of the guidelines) and algorithms. This complete report is available online at ESGO/ESTRO/ESP Web sites (https:// guidelines.esgo.org/, https://www.estro.org/, https://www. esp-pathology.org/publications/guidelines.html, https://www. esp-pathology.org/working-groups/esp-working-groups/ gynecologic-pathology.html).
General recommendations
& Treatment planning should be made on a multidisciplinary basis (generally at a tumor board meeting) and based on the comprehensive and precise knowledge of prognostic and predictive factors for oncological outcome, morbidity, and quality of life. Recommended best practice based on the clinical experience of the guideline development group 1++ = High-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias; 1+ = well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias; 2++ = high-quality systematic reviews of case-control or cohort studies or highquality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal; 2+ = wellconducted casecontrol or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal; 3 = nonanalytic studies, for example, case reports, case series; 4 = expert opinion.
cervical cancer with negative para-aortic lymph nodes on imaging for staging purposes (grade C). & Equivocal extrauterine disease is to be considered for biopsy to confirm or rule out metastatic disease and to avoid inappropriate treatment. Tru-Cut (core-cut) biopsy is the preferred option than fine-needle aspiration biopsy because it allows histological assessment of the tissue.
Management of stage T1a
Diagnosis of stage T1a disease Patients should be referred for definitive chemoradiotherapy. Para-aortic lymph node dissection, at least up to inferior mesenteric artery, may be considered for staging purposes (grade C). & If a combination of risk factors is known at diagnosis, which would require an adjuvant treatment, definitive radiochemotherapy and brachytherapy can be considered without previous radical pelvic surgery. Pelvic lymph node dissection, at least up to inferior mesenteric artery, may be considered in patients with negative para-aortic lymph node on imagine (grade C).
Negative lymph nodes on radiological staging -Alternative treatment options & Definitive radiotherapy including brachytherapy represents effective alternative treatment (see PRINCIPLES OF RADIOTHERAPY). It can be considered in particular in case of unfavorable prognostic and predictive factors for oncological and morbidity outcome (grade C). & For high risk and intermediate risk, preoperative brachytherapy followed by surgery (type A) is used in a limited number of centers. It is an acceptable alternative option only in teams experienced in this approach. & Neoadjuvant chemotherapy followed by surgery is not recommended (grade C).
Positive pelvic lymph nodes on radiological staging & In patients with unequivocally involved pelvic lymph nodes on imaging, definitive chemoradiotherapy is recommended (see PRINCIPLES OF RADIOTHERAPY). Para-aortic lymph node dissection, at least up to inferior mesenteric artery, may be considered in patients with negative para-aortic lymph nodes on imaging (grade C). & Debulking of suspicious pelvic lymph nodes may be considered.
Adjuvant treatment
& Adjuvant radiotherapy should be considered in the presence of combination of risk factors at final pathology such as tumor size, LVSI, and depth of stromal invasion (grade B). & When in these situations an adequate type of radical hysterectomy has been performed (Table 4) , observation is an alternative option, especially in teams experienced in this approach.
After primary radical surgery, adjuvant chemoradiotherapy is indicated in the following groups of patients (see PRINCIPLES OF RADIOTHERAPY) (grade B):
& metastatic involvement of pelvic lymph nodes, including the presence of macrometastases pN1 or micrometastases pN1(mi) in either sentinel node or any other pelvic lymph nodes detected by intraoperative or final pathologic assessment ⇨ chemoradiotherapy & positive surgical margins (vagina/parametria) ⇨ chemoradiotherapy, brachytherapy boost may be considered & parametrial involvement ⇨ chemoradiotherapy
Cervical stump cancer
& Management of cervical stump cancer follows the recommendations for patients without previous subtotal hysterectomy. Adaptation of radiotherapy may be necessary, in particular for brachytherapy. However, no imaging system can exactly predict the extent of necessary local resection in order to reach sound margins with adequate safety distance. & Negative pelvic lymph node status is the precondition for any FST. Therefore, pelvic lymph node (sentinel lymph node) staging should always be the first step in each FST procedure. Identification of sentinel lymph node and its ultrastaging is highly recommended because it increases staging accuracy, namely, the identification of micrometastases and small macrometastases. The involvement of suspicious lymph nodes should be confirmed by histology. Intraoperative assessment of lymph node status is highly recommended. All sentinel lymph nodes from both sides of the pelvis or any suspicious lymph nodes should be sent for frozen section. If bilateral sentinel lymph node is not detectable, intraoperative assessment of pelvic lymph nodes should be considered (see MANAGEMENT OF STAGES T1b1/T2a1). Lymph node staging is not indicated in stage T1a1 LVSI negative (grade B). & In case of intraoperatively proven lymph node involvement, fertility-sparing surgery should be abandoned, and the patient referred to definitive chemoradiotherapy (see above). The specific aim of fertility-sparing surgery must be the resection of invasive tumor with adequate free margins and preservation of the upper part of the cervix. In absence of residual tumor on imaging (including suspicious lymph nodes), radiotherapy alone is recommended.
In case of residual tumor on imaging, including suspicious lymph nodes, chemoradiotherapy is recommended (grade D). & Para-aortic lymph node dissection, at least up to inferior mesenteric artery, may be considered in patients without suspicious para-aortic nodes on imaging for staging purposes (grade C). & Debulking of suspicious pelvic lymph nodes may be considered. & Radical surgery is an option in patients without lymph node involvement on imaging and in the absence of an upfront indication for adjuvant radiotherapy (combination of negative prognostic factors (grade D). & Pelvic lymph node dissection should be performed as the first step of the surgery. Intraoperative assessment of pelvic lymph nodes may be considered. If intraoperative lymph node assessment is negative or is not performed, radical parametrectomy with the resection of the upper vagina should be performed preferably using minimally invasive techniques. The type of radical parametrectomy (extent of parametrial resection) should be tailored to the presence of prognostic risk factors of the primary tumor as described above (Table 3) . & Complete description of the template used for radical parametrectomy should be present in the operative report. & The 2017 modification of the Querleu-Morrow classification is recommended as a tool (Table 4) . & If lymph node involvement, including macrometastases or micrometastases, is detected intraoperatively, further surgery (pelvic lymph node dissection and radical parametrectomy) should be avoided, and chemoradiotherapy is recommended (grade D). Para-aortic lymph node dissection, at least up to inferior mesenteric artery, may be considered for staging purposes (grade C). Debulking of suspicious nodes may be considered.
Management of patients with pT1b2 and higher or involved surgical margins or residual tumor including involved lymph node on imaging & In patients with stage pT1b2 and higher, involved surgical margins or in those with residual tumor including involved lymph node on imaging, chemoradiotherapy is recommended, and further surgery should be avoided. & Para-aortic lymph node dissection, at least up to inferior mesenteric artery, may be considered for staging purposes in patients with negative para-aortic lymph nodes on imaging (grade C). & Debulking of suspicious pelvic lymph nodes may be considered.
Management of locally advanced cervical cancer
Stage T1b2/T2a2 and negative lymph nodes on radiological staging & Treatment strategy should aim for avoiding the combination of radical surgery and postoperative external radiotherapy because of the significant increase in morbidity and no evident impact on survival (grade B). & Definitive platinum-based chemoradiotherapy and brachytherapy are the preferred treatment (see PRINCIPLES OF RADIOTHERAPY) (grade A). & Para-aortic lymph node dissection, at least up to inferior mesenteric artery, may be considered before chemoradiotherapy and brachytherapy. Pelvic lymph node dissection is not required (grade C). & Radical surgery is an alternative option, in particular in patients without negative risk factors (combinations of tumor size, LVSI, and/or depth of stromal invasion). Quality of surgery, both parametrectomy and lymph node dissection, is, however, of key importance in the management of large tumors. Intraoperative assessment of lymph node status (frozen section) is recommended as the first step. If lymph node involvement is detected intraoperatively, including macrometastases or micrometastases, further pelvic lymph node dissection and radical hysterectomy should be avoided, and patients should be referred for definitive chemoradiotherapy and brachytherapy. Para-aortic lymph node dissection, at least up to inferior mesenteric artery, maybe considered for staging purposes. If intraoperative lymph node assessment is negative or is not done, systematic pelvic lymph node dissection should be performed. Type C2 radical hysterectomy is recommended.
& Neoadjuvant chemotherapy followed by radical surgery is a controversial alternative. The benefit of tumor downsizing with regard to prognosis has not been proven (grade C). & Reirradiation with IGABT for central recurrences is an alternative option especially in patients unfit for or refusing exenteration surgery, which should be restricted to highly specialized centers.
Curative intent treatment -role of chemotherapy & If further surgery or radiotherapy is considered, no more than 2 to 4 courses of combination chemotherapy should be given to avoid unnecessary long interval before definitive treatment. Locoregional recurrences, which at diagnosis appear incurable, should be reassessed for the possibility of radical treatment if major response is obtained. & Suitable candidates for adjuvant chemotherapy are patients who recover well within 2 months after primary treatment for recurrence.
Curative intent treatment -nodal and oligometastatic recurrences
& Localized para-aortic, mediastinal, and/or periclavicular recurrences above previously irradiated fields may be treated by radical external beam radiotherapy (EBRT) if possible in combination with concomitant chemotherapy.
It is recommended to electively irradiate the immediate regional nodal stations below and upstream.
& The therapeutic effect of nodal resection/debulking is unclear and should, if possible, always be followed by radiotherapy. & The management of isolated organ metastases (lung, liver, etc) should be discussed in a multidisciplinary team involved in the treatment of the specific organ affected by the metastasis and should be treated according to the preferred method for that organ involving local resection, radiofrequency ablation, interventional brachytherapy, or stereotactic ablative radiotherapy according to size and anatomical position.
Palliative treatment
& Recommendations for palliative treatment should be made only after a thorough review of the case by a specialist multidisciplinary team and taking into account the performance status, comorbidities, patient's symptoms, and wishes of the patient. The palliative care specialist should be actively involved. & Palliative taxane/platinum combination chemotherapy with/ without bevacizumab is the preferred option (grade B). 
Follow-up
General recommendations Follow-up after fertility-sparing treatment & All women remain at risk of tumor recurrence following FST and must be carefully followed up. Follow-up should be carried out by a provider with specific expertise in detection of lower genital tract dysplasia (eg, gynecologic oncologist, colposcopy expert). & Follow-up intervals should be 3 to 4 months for the first 2 years postoperatively, and then 6 to 12 months up to 5 years. Thereafter the patient may return to populationbased screening. The duration of follow-up, however, may be individualized depending on the risk of recurrence or persistence of treatment-related complications (grade C).
& Follow-up should include HPV testing (with or without cytology). Colposcopy in combination with HPV testing in parallel performed by an experienced colposcopist is an option. The incorporation of high-risk HPV testing at 6, 12, and 24 months after treatment is advocated. If HPV testing is negative, then every 3 to 5 years as long as follow-up is indicated (grade C).
Follow-up after simple or radical hysterectomy & Follow-up should be carried out by physician experienced with follow-up care after surgery following the general recommendations (see above). The vaginal vault cytology is not recommended.
Follow-up after definitive Chemoradiotherapy
& The same imaging method should be used for evaluation of tumor response as was used at baseline. & Imaging should be performed not earlier than 3 months following completion of treatment. In dubious cases, a reevaluation should be performed not before 8 weeks thereafter. & For re-evaluation purposes, the optimal diagnostic workup for local extent is pelvic MRI, and for distant spread, it is chest/abdomen CT or PET-CT (preferred after definitive chemoradiotherapy or in high-risk patients) (grade B). & Follow-up should be performed by a physician experienced with follow-up care after radiotherapy. Cytology is not recommended in these patients. & Providers should inform and educate on sexual and vaginal health because vaginal stenosis and dryness may occur. Vaginal dilation should be offered, as well as vaginal lubricants and local estrogen.
Cervical cancer in pregnancy
& Every patient diagnosed with CCIP must be counseled by a multidisciplinary team. This team should consist of experts in the fields of gynecologic oncology, neonatology, obstetrics, anesthesiology, radiation oncology, medical oncology, psychooncology, and, if requested, theology or ethics. & Given the large spectrum of described therapeutic options, the multidisciplinary team recommends an individual consensual treatment plan according to patient's intention, tumor stage, and gestational age of pregnancy at cancer diagnosis. Primary aims of recommended treatment plan are oncological safety of the pregnant woman, as well as survival without additional morbidity of the fetus.
& Treatment of patients with CCIP should exclusively be done in gynecologic oncology centers associated with a highest level perinatal center with expertise in all aspects of oncologic therapy in pregnancy and intensive medical care of premature neonates. Because of the low incidence of CCIP, centralization in a few well-equipped facilities is compulsory. & Besides clinical examination and histologic verification of invasive cervical cancer, preferred imaging modalities for clinical staging in patients with CCIP include MRI or expert ultrasound. Because of limited experience and inherent radioactivity PET-CT (PET-MRI) should be indicated only under very selected circumstances (grade D). & Tumor involvement of suspicious nodes should be verified histologically because of its prognostic significance and the impact on the management up to 24th week of gestation (fetal viability), preferably by minimally invasive approach.
Depending on tumor stage and gestational week of pregnancy, the following treatment options have to be discussed with the patient including risks and benefits of individual approaches (grade D):
& Adapted surgery including removal of the tumor: conization, trachelectomy, and lymph node staging (see above) according to the stage of the disease with the intent to preserve the pregnancy. & Radical surgery or definitive chemoradiation as recommended for the stage of the disease without preservation of the pregnancy, with or without previous pregnancy termination. & Delay of oncological treatment until fetal maturity (if possible 932 weeks of gestation) and beginning of cancerspecific treatment immediately after delivery by cesarean section. & Chemotherapy until fetal maturity and beginning of cancer-specific treatment immediately after delivery by cesarean section. Treatment after delivery must consider application of previous chemotherapy. In patients with locally advanced stage or with residual tumor after conization that cannot be completely excised (risk of premature rupture of membranes and/or cervical insufficiency), platinum-based chemotherapy can be considered starting earliest at 14 weeks of gestation. & Spontaneuous delivery seems to have negative prognostic impact in patients with CCIP. Thus, cesarean section after the 32nd week of gestation (if possible) is the recommended mode of delivery. At the time of or following casarean section, definitive stage-adjusted oncologic therapy has to be performed corresponding to that of nonpregnant women, taking into account therapy that has already been given during pregnancy (grade D). 
Principles of radiotherapy

Definitive chemoradiotherapy
& External beam radiotherapy is recommended minimum as 3-dimensional (3D) conformal radiotherapy. The preferred treatment is intensity-modulated radiotherapy (IMRT) because of the more conformal dose distribution that maximizes sparing of organs at risk. & External beam radiotherapy can be applied as concomitant chemoradiotherapy with total dose of 45 to 50 Gy (1.8 Gy per fraction) and single-agent radiosensitizing chemotherapy, preferably cisplatin (weekly 40 mg/m 2 ) so that definitive radiotherapy is not compromised. If cisplatin is not applicable, alternative treatment options are fluorouracil or carboplatin. External beam radiotherapy may also be applied without concomitant chemotherapy according to treatment selection (ie, patients unfit for any chemotherapy). In such cases, regional hyperthermia may be considered. & Tumor and lymph node-related target volume for IMRT includes the primary cervical tumor and the adjacent tissues such as parametria, uterine corpus, upper vagina, and the pelvic lymph nodes (obturator, internal, external and common iliac, presacral) . In case of pelvic lymph node involvement indicating an increased risk of para-aortic lymph node spread, EBRT may include the para-aortic region up to the renal vessels (45 Gy). In case of paraaortic lymph node involvement, target volume includes at a minimum the region up to the renal vessels. & A reduced target volume for EBRT resulting in a small pelvic field not including the common iliac nodes may be considered in low-and intermediate-risk T1b1 patients with negative lymph nodes on imaging and no LVSI. & Boost treatment for involved lymph node(s) may be applied as simultaneous integrated boost within the IMRT treatment or as sequential boost. The total dose including the contribution from brachytherapy should be 55 to 60 Gy (equieffective dose to 2 Gy per fraction [EQD2] ). An alternative treatment option is surgical debulking of enlarged nodes.
& Image-guided radiotherapy (IGRT) is recommended for IMRT to ensure safe dose application in the tumor-related targets, to account for motion uncertainties, to reduce margins, and to achieve reduced doses to organs at risk. & Overall treatment time for EBRT should not exceed 5 to 6 weeks.
Definitive brachytherapy
& Image-guided adaptive brachytherapy is recommended, preferably using MRI at the time of brachytherapy. Image-guided adaptive brachytherapy is delivered in large tumors toward the end of or after concomitant chemoradiotherapy. Repeated gynecologic examination is mandatory, and alternative imaging modalities such as CT and ultrasound may be used. The brachytherapy application should be a combined intracavitary/interstitial approach in order to achieve a sufficiently high radiation dose in the whole CTV-T HR . & In IGABT, the planning aim should be to deliver a brachytherapy dose of 40 to 45 Gy (EQD2) to reach a total EBRT+ brachytherapy dose of equal to or greater than 85 to 90 Gy EQD2 (D90) (assuming 45 Gy through EBRT) to the CTV-T HR , equal to or greater than 60 Gy (D98) to the CTV-T IR , and equal to or greater than 90 Gy (D98) to the GTV-T res .Three-dimensional and 2D dose volume and point constraints for rectum, bladder, vagina, sigmoid, and bowel are recommended, and they have to be based on the published clinical evidence. & Point A dose normalization should be used as starting point for stepwise treatment plan optimization, although point A dose reporting and prescription have been extended by the volumetric approach.
& Brachytherapy should be delivered in several fractions as high dose rate (usually 3-4) or in 1 to 2 fractions as pulse dose rate brachytherapy. & In large tumors, brachytherapy should be delivered within 1 to 2 weeks toward the end of or after chemoradiotherapy. In limited-size tumors, brachytherapy may start earlier during chemoradiotherapy. & For the tumor-related targets (GTV-T res , CTV-T HR , CTV-T IR ), the use of external beam therapy for giving extra dose (eg, parametrial boost, cervix boost) is discouraged, even when using advanced EBRT technology such as stereotactic radiotherapy. The use of a midline block for boosting the parametrium is discouraged when applying advanced IGRT, in particular beyond 45 to 50 Gy. & Care should be taken to optimize patient comfort during (fractionated) brachytherapy. Preferably this includes a multidisciplinary approach.
Adjuvant radiotherapy or chemoradiotherapy
& Adjuvant radiotherapy or chemoradiotherapy follows analog principles for target selection and dose and fractionation as outlined for definitive treatment. & The application of IMRT and IGRT is to be considered as treatment-related morbidity may be reduced. & Adjuvant (additional) brachytherapy should be considered only if a well-defined limited area -accessible through a brachytherapy technique -is at high risk of local recurrence (eg, vagina, parametrium). Such adjuvant brachytherapy should follow the major principles outlined above for image-guided brachytherapy.
Definitive 3D conformal EBRT or chemoradiotherapyand radiography-based brachytherapy & Three-dimensional conformal radiotherapy alone or as definitive concomitant chemoradiotherapy (platinum based) ± para-aortic radiotherapy and/or 2D radiography-based brachytherapy is recommended, if IMRT and/or IGABT are not available. & In case of 3D conformal radiotherapy and/or radiographybased brachytherapy, the recommendations for EBRT and IGABT as outlined above in regard to target, dose, fractionation, and overall treatment time have to be respected as much as possible. & A sequential lymph node boost is applied as appropriate after completion of 3D EBRT. & Planning aim for brachytherapy should be based on point A. Dose to point A should be equal to or greater than 75 Gy (EQD2) in limited width adaptive CTV-T HR (≤3 cm) and should aim at higher doses in large width adaptive CTV-T HR (>4 cm). In addition, dose for the maximum width of the adaptive CTV-T HR should be reported. Radiography-based dose point constraints -plus 3D dose volume constraints as available -for rectum, bladder, vagina, sigmoid, and bowel are recommended, and they have to be based on the published clinical evidence.
Principles of pathological evaluation
Requirements for specimen submitted for pathological evaluation 
Pathological analysis of sentinel lymph node
& Intraoperative assessment should be performed on a grossly suspicious sentinel node and may be performed on a "nonsuspicious" sentinel lymph node(s) because the confirmation of tumor involvement will result in abandoning a hysterectomy or trachelectomy. & For intraoperative evaluation, the sentinel lymph node(s) needs to be sent to the pathology department in a container without liquid fixative. & Intraoperative analysis requires gross dissection of the resected adipose tissue by the pathologist with the selection of the lymph node(s Virchows Arch
